Ritter Pharmaceuticals Reports Financial Results for the Three and Nine Months Ended September 30, 2019 and Provides Business Update
13 nov. 2019 19h35 HE
|
Ritter Pharmaceuticals, Inc.
LOS ANGELES, Nov. 13, 2019 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of therapeutic products that modulate the gut...
Ritter Pharmaceuticals Announces Appointment of Andrew J. Ritter as Chief Executive Officer
27 juin 2018 07h05 HE
|
Ritter Pharmaceuticals, Inc.
LOS ANGELES, June 27, 2018 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of innovative therapeutic products that modulate...
Ritter Pharmaceuticals, Inc.’s Board Approves 1-for-10 Reverse Stock Split
01 mars 2018 16h20 HE
|
Ritter Pharmaceuticals, Inc.
Los Angeles, California, March 01, 2018 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a leading developer of novel therapeutic products...
Ritter Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Business Update
31 oct. 2017 06h45 HE
|
Ritter Pharmaceuticals, Inc.
LOS ANGELES, Oct. 31, 2017 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (NASDAQ:RTTR) (“Ritter Pharmaceuticals” or the “Company”), a pharmaceutical company developing novel therapeutic products...
Ritter Pharmaceuticals, Inc. Raises $23 Million to Fund Initiation of Its Phase 3 Clinical Program in Lactose Intolerance
03 oct. 2017 12h00 HE
|
Ritter Pharmaceuticals
Los Angeles, California,, Oct. 03, 2017 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a leading developer of novel therapeutic products...